GMP Securities

Troilus Gold is a Canadian development-stage resource company focused on the potential restart and mineral expansion of the former producing Troilus gold and copper mine in Quebec.

Troilus Gold is a Canadian development-stage resource company focused on the potential restart and mineral expansion of the former producing Troilus gold and copper mine in Quebec.

Eastmain Resources Inc. is a Canadian exploration-stage company focused on the acquisition and exploration of metallic mineral resource properties, primarily targeting gold and other base metals. Established in 1982 and headquartered in Toronto, Eastmain's flagship project is the Clearwater project, situated in the James Bay region of Québec. The company is actively involved in exploring several other projects in central James Bay, including the Eastmain Mine, Eleonore South Joint Venture, and Lac Lessard, among others. Eastmain prioritizes aggressive exploration strategies to identify world-class ore deposits and has established joint-venture partnerships with prominent mining companies to leverage their financial resources and technical expertise. With a strong commitment to advancing its projects within the mineral-rich regions of Ontario and Québec, Eastmain aims to capitalize on the significant unmined mineral wealth of these areas.

Troilus Gold is a Canadian development-stage resource company focused on the potential restart and mineral expansion of the former producing Troilus gold and copper mine in Quebec.

Troilus Gold is a Canadian development-stage resource company focused on the potential restart and mineral expansion of the former producing Troilus gold and copper mine in Quebec.

Integra Resources is a development-stage company focused on acquiring, exploring, and developing mineral properties in the Americas. Its primary asset is the DeLamar project in southwestern Idaho, which includes the DeLamar and Florida Mountain gold-silver deposits.

Knight Therapeutics Inc. is a specialty pharmaceutical company based in Montreal, Canada, engaged in the development, acquisition, in-licensing, out-licensing, marketing, and distribution of innovative prescription pharmaceuticals, consumer health products, and medical devices. The company offers a range of commercialized products, including Movantik for opioid-induced constipation, Mytesi for noninfectious diarrhea in adults with HIV or AIDS, NERLYNX for HER2-positive breast cancer, and Trelstar for prostate cancer. Additionally, Knight Therapeutics is involved in the development of treatments for conditions such as opioid addiction, chronic pain, diabetes-related eye diseases, and neurological disorders. Their product pipeline includes various therapies targeting acute migraine, HPV-associated cancers, and osteoarthritis-related pain, among others. Founded in 2013, Knight Therapeutics continues to expand its portfolio and invest in innovative life sciences solutions both in Canada and internationally.

Knight Therapeutics Inc. is a specialty pharmaceutical company based in Montreal, Canada, engaged in the development, acquisition, in-licensing, out-licensing, marketing, and distribution of innovative prescription pharmaceuticals, consumer health products, and medical devices. The company offers a range of commercialized products, including Movantik for opioid-induced constipation, Mytesi for noninfectious diarrhea in adults with HIV or AIDS, NERLYNX for HER2-positive breast cancer, and Trelstar for prostate cancer. Additionally, Knight Therapeutics is involved in the development of treatments for conditions such as opioid addiction, chronic pain, diabetes-related eye diseases, and neurological disorders. Their product pipeline includes various therapies targeting acute migraine, HPV-associated cancers, and osteoarthritis-related pain, among others. Founded in 2013, Knight Therapeutics continues to expand its portfolio and invest in innovative life sciences solutions both in Canada and internationally.

Integra Gold Corp. is a Vancouver-based provider of gold exploration services. The company develops and manages exploration projects and mining operations, with a focus on the Val‑d’Or region of Québec, one of Canada’s leading mining jurisdictions. Its services include site assessment, drilling, and resource evaluation, enabling clients to identify and develop potential gold deposits.

Integra Gold Corp. is a Vancouver-based provider of gold exploration services. The company develops and manages exploration projects and mining operations, with a focus on the Val‑d’Or region of Québec, one of Canada’s leading mining jurisdictions. Its services include site assessment, drilling, and resource evaluation, enabling clients to identify and develop potential gold deposits.

Integra Gold Corp. is a Vancouver-based provider of gold exploration services. The company develops and manages exploration projects and mining operations, with a focus on the Val‑d’Or region of Québec, one of Canada’s leading mining jurisdictions. Its services include site assessment, drilling, and resource evaluation, enabling clients to identify and develop potential gold deposits.

Knight Therapeutics Inc. is a specialty pharmaceutical company based in Montreal, Canada, engaged in the development, acquisition, in-licensing, out-licensing, marketing, and distribution of innovative prescription pharmaceuticals, consumer health products, and medical devices. The company offers a range of commercialized products, including Movantik for opioid-induced constipation, Mytesi for noninfectious diarrhea in adults with HIV or AIDS, NERLYNX for HER2-positive breast cancer, and Trelstar for prostate cancer. Additionally, Knight Therapeutics is involved in the development of treatments for conditions such as opioid addiction, chronic pain, diabetes-related eye diseases, and neurological disorders. Their product pipeline includes various therapies targeting acute migraine, HPV-associated cancers, and osteoarthritis-related pain, among others. Founded in 2013, Knight Therapeutics continues to expand its portfolio and invest in innovative life sciences solutions both in Canada and internationally.

Knight Therapeutics Inc. is a specialty pharmaceutical company based in Montreal, Canada, engaged in the development, acquisition, in-licensing, out-licensing, marketing, and distribution of innovative prescription pharmaceuticals, consumer health products, and medical devices. The company offers a range of commercialized products, including Movantik for opioid-induced constipation, Mytesi for noninfectious diarrhea in adults with HIV or AIDS, NERLYNX for HER2-positive breast cancer, and Trelstar for prostate cancer. Additionally, Knight Therapeutics is involved in the development of treatments for conditions such as opioid addiction, chronic pain, diabetes-related eye diseases, and neurological disorders. Their product pipeline includes various therapies targeting acute migraine, HPV-associated cancers, and osteoarthritis-related pain, among others. Founded in 2013, Knight Therapeutics continues to expand its portfolio and invest in innovative life sciences solutions both in Canada and internationally.